NCT06381141View on ClinicalTrials.gov

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

CLN-619

Anti-MICA/MICB monoclonal antibody

Trial Locations (8)

10029

Mt. Sinai, New York

10065

Memorial Sloan Kettering (MSK), New York

27157

Levine Cancer Institute, Winston-Salem

28204

Levine Cancer Institute, Charlotte

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

75390

University of Texas Southwestern Medical Center, Dallas

85054

Mayo Clinic, Phoenix

Sponsors
All Listed Sponsors
lead

Cullinan Therapeutics Inc.

INDUSTRY

NCT06381141 - A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter